Abstract
Autoimmunity is an overreaction of immune competent cells to self structures resulting in an unwanted clinical outcome. Traditional therapeutic strategies, still relevant in many cases, involve broad acting immunosuppressants such as cyclophosphamide with the predictable attendant toxicity. More recent concepts include blockade of specifically defined targets such as TNF-α, with resulting immunomodulation and less toxicity. Both of these strategies require ongoing drug treatment of established disease.
A long standing goal, not yet achieved, is the predictable induction of tolerance, obviating the need for chronic treatment. Experimental strategies to achieve this include pre-emptive (preclinical) treatment before chronification is established, total immune ablation and immune “resetting“ and autoantigen immunisation.
Keywords: Autoimmune disease, biologics, stem cell transplantation, autoimmunity, immune competent cells, immunosuppressants, cyclophosphamide, TNF-α, immunomodulation, toxicity.
Current Pharmaceutical Design
Title:Modern Therapeutic Strategies for Autoimmune Diseases
Volume: 18 Issue: 29
Author(s): Alan Tyndall
Affiliation:
Keywords: Autoimmune disease, biologics, stem cell transplantation, autoimmunity, immune competent cells, immunosuppressants, cyclophosphamide, TNF-α, immunomodulation, toxicity.
Abstract: Autoimmunity is an overreaction of immune competent cells to self structures resulting in an unwanted clinical outcome. Traditional therapeutic strategies, still relevant in many cases, involve broad acting immunosuppressants such as cyclophosphamide with the predictable attendant toxicity. More recent concepts include blockade of specifically defined targets such as TNF-α, with resulting immunomodulation and less toxicity. Both of these strategies require ongoing drug treatment of established disease.
A long standing goal, not yet achieved, is the predictable induction of tolerance, obviating the need for chronic treatment. Experimental strategies to achieve this include pre-emptive (preclinical) treatment before chronification is established, total immune ablation and immune “resetting“ and autoantigen immunisation.
Export Options
About this article
Cite this article as:
Tyndall Alan, Modern Therapeutic Strategies for Autoimmune Diseases, Current Pharmaceutical Design 2012; 18 (29) . https://dx.doi.org/10.2174/138161212802502170
DOI https://dx.doi.org/10.2174/138161212802502170 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Topical Nanocarriers for Treatment of Psoriasis: An Overview
Current Pharmaceutical Design Epigenetics in Ocular Diseases
Current Genomics Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism Deaza Analogs of Folic Acid as Antitumor Agents
Current Pharmaceutical Design The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Oral Contraceptives and Autoimmune Diseases
Current Women`s Health Reviews Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Regulation of B-Cell Activation by Complement Receptors CD21 and CD35
Current Pharmaceutical Design Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design The Role of Autophagy in Rheumatic Disease
Current Drug Targets Purine Nucleoside Phosphorylase: A Potential Target for the Development of Drugs to Treat T-Cell- and Apicomplexan Parasite-Mediated Diseases
Current Drug Targets Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far
Mini-Reviews in Medicinal Chemistry Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges
Current Drug Discovery Technologies Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Control of Autoimmune Diseases by the B7-CD28 Family Molecules
Current Pharmaceutical Design